Equity
Thermo Fisher Scientific·Balance Sheet Statement·8 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities and stockholders' equity | $98.5B | $100.4B | $97.3B | $99.0B | $101.2B | $103.0B | $110.3B | $113.3B |
| Retained earnings | $49.9B | $51.4B | $53.1B | $54.4B | $55.9B | $57.4B | $59.2B | $60.6B |
| Total stockholders' equity | $47.4B | $49.0B | $49.6B | $49.4B | $50.5B | $51.0B | $53.4B | $51.9B |
| Treasury stock | $18.2B | $18.2B | $19.2B | $21.3B | $21.3B | $22.3B | $22.3B | $25.4B |
| Additional paid-in capital | $17.6B | $17.8B | $18.0B | $18.1B | $18.2B | $18.3B | $18.6B | $18.7B |
| Accumulated other comprehensive income (loss) | -$2.4B | -$2.5B | -$2.7B | -$2.3B | -$2.8B | -$2.8B | -$2.4B | -$2.5B |
| Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | $443.0M | $444.0M | $444.0M | $444.0M | $444.0M | $445.0M | $445.0M | $445.0M |
| Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |